Cortexyme Inc. (CRTX)

23.78
NASDAQ : Health Technology
Prev Close 24.48
Day Low/High 23.51 / 24.97
52 Wk Low/High 19.50 / 47.50
Avg Volume 78.20K
Exchange NASDAQ
Shares Outstanding 26.84M
Market Cap 657.07M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cortexyme's Approach To Addressing A Key Underlying Cause Of Alzheimer's Detailed At Alzheimer's Association International Conference 2019

Cortexyme's Approach To Addressing A Key Underlying Cause Of Alzheimer's Detailed At Alzheimer's Association International Conference 2019

Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of clinical data that supports its ongoing work to pioneer a novel, disease-modifying therapeutic approach to treating a key underlying cause of Alzheimer's and other degenerative diseases.

Cortexyme Announces Upcoming Data Presentations At The Alzheimer's Association International Conference 2019

Cortexyme Announces Upcoming Data Presentations At The Alzheimer's Association International Conference 2019

Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative diseases will be discussed in two research abstracts at the...

Cortexyme Expands Clinical Advisory Board With Key Clinical And Regulatory Experts

Cortexyme Expands Clinical Advisory Board With Key Clinical And Regulatory Experts

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative diseases, today announced four new additions to its...

Cortexyme To Present At National Academies Forum On Tuesday, June 11, 2019

Cortexyme To Present At National Academies Forum On Tuesday, June 11, 2019

Cortexyme, Inc. (Nasdaq: CRTX) today announced that Casey Lynch, the company's chief executive officer, chairman, and co-founder, will present at a National Academies of Science, Engineering, and Medicine workshop on the growing understanding of the...

Cortexyme, Inc. Announces Closing Of Initial Public Offering And The Exercise Of The Underwriters' Option To Purchase Additional Shares

Cortexyme, Inc. Announces Closing Of Initial Public Offering And The Exercise Of The Underwriters' Option To Purchase Additional Shares

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative diseases, today announced the closing of its initial...

Cortexyme, Inc. Announces Pricing Of Initial Public Offering

Cortexyme, Inc. Announces Pricing Of Initial Public Offering

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative diseases, today announced that it has priced its...

Top Insider Trades: PSX YRCW CRTX IDIX

Top Insider Trades: PSX YRCW CRTX IDIX

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Ratings Changes Today

Upgrades: CRTX, EXPE, FARM, IEP, MCF, NRP, SCR, VLCCF, YPF Downgrades: ACTG, BPT, IPAS, MWV, SPRT, SVM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Law Firm Brower Piven Announces Class Action Lawsuit In Connection With Claims Of Breaches Of Fiduciary Duty By The Board Of Cornerstone Therapeutics, Inc. In Connection With A Proposed Buyout

Law Firm Brower Piven Announces Class Action Lawsuit In Connection With Claims Of Breaches Of Fiduciary Duty By The Board Of Cornerstone Therapeutics, Inc. In Connection With A Proposed Buyout

The securities litigation firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders ...

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cornerstone Therapeutics, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cornerstone Therapeutics, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cornerstone Therapeutics, Inc.

Shareholder Rights Law Firm Johnson & Weaver, LLP, Is Investigating The Cornerstone Buyout

Shareholder Rights Law Firm Johnson & Weaver, LLP, Is Investigating The Cornerstone Buyout

Shareholder rights law firm Johnson & Weaver, LLP is investigating potential breaches of fiduciary duty in connection with the proposed buyout of North Carolina-based Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Chiesi Farmaceutici

Cornerstone Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Chiesi Farmaceutici

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating the acquisition of Cornerstone Therapeutics, Inc.

Law Firm Brower Piven Announces Investigation Of Cornerstone Therapeutics, Inc. Proposed Acquisition

Law Firm Brower Piven Announces Investigation Of Cornerstone Therapeutics, Inc. Proposed Acquisition

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Cornerstone Therapeutics, Inc.

Finkelstein Thompson LLP Announces Investigation Of Cornerstone Therapeutics Inc. Buyout

Finkelstein Thompson LLP Announces Investigation Of Cornerstone Therapeutics Inc. Buyout

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Cornerstone Therapeutics Inc.

5 Biotech Stocks Under $10 Making Big Moves

5 Biotech Stocks Under $10 Making Big Moves

Keep these biotech stocks on your radar.

4 Health Care Stocks Under $10 Close to Breakouts

4 Health Care Stocks Under $10 Close to Breakouts

Keep these health care stocks on your radar.

Commit To Buy Cornerstone Therapeutics At $7.50, Earn 18.7% Annualized

Commit To Buy Cornerstone Therapeutics At $7.50, Earn 18.7% Annualized

Investors eyeing a purchase of Cornerstone Therapeutics Inc stock, but tentative about paying the going market price of $8.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 50 cents.

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

Cornerstone Therapeutics (Nasdaq:CRTX) has been upgraded by TheStreet Ratings from a sell to hold.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cornerstone Therapeutics Inc. Shareholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cornerstone Therapeutics Inc. Shareholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Shareholder Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Going Private Proposal

Cornerstone Therapeutics Shareholder Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Going Private Proposal

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of...

31 Drugs Facing FDA Approval in 2012-2013

31 Drugs Facing FDA Approval in 2012-2013

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012 and early 2013

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

4 Biotech Stocks Under $10 With Relative Strength

4 Biotech Stocks Under $10 With Relative Strength

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Cornerstone Therapeutics Inc. Stock Downgraded (CRTX)

Cornerstone Therapeutics Inc. Stock Downgraded (CRTX)

Cornerstone Therapeutics (Nasdaq:CRTX) has been downgraded by TheStreet Ratings from from a hold to sell.